Email Facebook Twitter

Exclusive: Hayden Locke, CEO Emmerson plc, a low cost high margin potash investment
Richard Slape, Oil consultant - Avoiding Losers and Picking Winners, his personal strategy

ShareCast News

Indivior plunges on profit warning after launch 'friction'

Wed, 11th Jul 2018 08:45

(Sharecast News) - Indivior issued a profit warning due to a slower than expected launch of a new product and changes in the US market for its main money-spinner, including challenges from a rival generic treatments.

On 15 June, rival Dr Reddy's Laboratories won approval from the US drug regulator for its generic version of Indivior's Suboxone Film for the treatment of opioid addiction and said it planned a launch imminently.

The FTSE 250-listed company applied for an injunction against Dr Reddy's to stop it from launching its generic version, pending the outcome of the recently filed litigation by the UK company related to its US patent number 9,931,305, but Indivior now "seeing the market impact" of Dr Reddy's generic sublingual film sold into the US market. But it does not know the exact quantity of product sold prior to the issuance of a temporary restraining order.

Until the impact of the rival launch is "better understood", Indivior said it now cannot reliably provide updated guidance, retracting the previously indicated expected revenue of $1.13-1.17bn and net profit of $280-320m.

Shares in Indivior fell almost 37% to below 250p on Wednesday morning.

A current rough estimation Dr Reddy's launch activities is seen producing around a negative $25m impact to net revenue, while higher rebates in generic tablets is resulting in discounting cutting prices 75-80% below list price.

This Managed Medicaid sales channel currently represents the majority of overall growth in the US market, has already resulted in lower than expected net revenue for the company, estimated to be at least $50m of net revenue impact.

Furthermore, another $50m impact is seen from a slower than expected launch of Sublocade, Indivior's new once-monthly version of the opioid addiction treatment, where there has been "some friction" in the new distribution and reimbursement model that has had an impact on physician willingness to prescribe at higher levels.

Chief executive Shaun Thaxter said: "Given the swift and material change in US market dynamics as well as the early-stage reimbursement and distribution model challenges we are experiencing with Sublocade, we are removing our FY 2018 net revenue and net income guidance.

"We are continuing to monitor US market developments to better gauge DRL's launch impact. We know that they are skilled in rapid distribution in quantity and, as such, there is a range of uncertainty around the amount of product they were able to ship before the temporary restraining order (TRO) was granted by the court. We are making progress in overcoming Sublocade's early stage challenges and continue to expect to deliver peak net revenue of $1bn-plus."

As a result, the company has begun to look at ways of cutting costs, initially targeting at least $25m in cost savings in 2018, to partially offset the financial impact of these developments.

Indivior's half-year results are due on 25 July, where more details on the above issues have been promised.

Related Shares:

Back to ShareCast News

Share Price, Share Chat, Stock Market news at
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.